04/07/2026
India’s GLP-1 market grew 4× in a year.
Then unit growth crashed from 88% to 12% — in a single month.
â‚ą100 crore in inventory. Unsold.
35 brands. 17 companies. 1 molecule.
Here’s the economic diagnosis no one wants to say out loud:
Supply followed the textbook. Demand refused to.
Classic economics promised: ↓ price → ↑ adoption. Prices fell 60–80%. Adoption didn’t follow — because the barriers were never financial. They were behavioral.
Three inertias pharma didn’t model:
→ Patients quitting at week 6 — nausea + unmet miracle expectations
→ GPs prescribing without counselling infrastructure = guaranteed dropout
→ No insurance for obesity — ₹3,000/month, forever, out-of-pocket
And yet — the most expensive brand is winning.
Tirzepatide = 63% of India’s total GLP-1 market.
Mounjaro = India’s #1 pharma brand by value, May 2026.
Behavioral economics beats price economics. Every time.
The drug works. The market infrastructure doesn’t.
Medicines don’t transform markets merely because they work. They transform markets when clinical value, affordability, physician confidence, and patient behavior reach equilibrium.
IndiaHealthcare BehavioralEconomics Tirzepatide HealthcareStrategy
